A
Abbisko Therapeutics
Abbisko Therapeutics is a drug company dedicated to innovative drug research and development
About Abbisko Therapeutics
Abbisko Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery and development of innovative small molecule therapies for oncology. Founded in 2016 and based in the Zhangjiang Hi-Tech Park in Shanghai, China, the company leverages a robust in-house R&D engine and a multi-dimensional discovery platform to advance its pipeline of 10 small molecule programs. Abbisko serves the oncology market, targeting unmet medical needs with differentiated therapies. The business model focuses on taking drug candidates from discovery through clinical development and commercialization, generating revenue through partnerships, licensing agreements, and eventual product sales. The company is led by a seasoned management team with extensive experience in drug discovery and development, ensuring a strategic approach to bringing new treatments to market.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Pudong, China
- Employees
- 49
- Open positions
- 2
- Dealroom signal
- 72.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Oct 2021 | $226M | $1.1B | Undisclosed | — |
| SERIES DOther financing | Jan 2021 | $123M | $492M | Warburg Pincus · CICC · Sage Partners · The Carlyle Group | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Abbisko Therapeutics is 3.9K monthly website visits, up 200% over the last three months. Abbisko Therapeutics's team declined 3.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Abbisko Therapeutics in the Pudong ecosystem
The Abbisko Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Lilly Asia Ventures
TF Capital
Qiming Venture Partners
CICC
Loyal Valley Capital
Series B and later9 investors entered at this stage
Temasek
GIC- JCJianxin Capital
Warburg Pincus
Sage Partners
The Carlyle Group
OrbiMed
Lake Bleu Capital
Janchor Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Abbisko Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Abbisko Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










